NCT03341637 - Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) in Adolescents in Non-Endemic Area(s) | Biotech Hunter

Enrollment

400

Participants

Timeline

Start Date

December 14, 2017

Primary Completion Date

January 26, 2019

Study Completion Date

January 26, 2019

Conditions

Dengue

Interventions

BIOLOGICAL

Tetravalent Dengue Vaccine (TDV)

TDV subcutaneous injection

BIOLOGICAL

Placebo

Normal Saline (0.9% NaCl) subcutaneous injection

Trial Locations (5)

Instituto Nacional de Pediatria (INP), Mexico City

Hospital Infantil de Mexico Federico Gomez, Mexico City

Biodextra, S.A. de C.V., Mexico City

Mexico Centre for Clinical Research, Mexico City

Centro de Atencion E Investigacion Medica (CAIMED) Mexico DF, Mexico City